Dr. Killebrew joined Good Therapeutics in 2018 and currently serves as Director of Immuno-Oncology Discovery. He brings over 15 years of immunology and oncology focused research and drug development experience. Before joining Good, Dr. Killebrew was Director of the Discovery Biology group at Silverback Therapeutics, where he oversaw in vitro and in vivo research in support of their lead ADC program.
Prior to Silverback, he held positions of increasing responsibility within the research organization at Bristol-Myers Squibb, where he advanced multiple therapeutic programs within the areas of Immuno-Oncology and Immunoscience. Dr. Killebrew received his Ph.D. in Immunology from the University of Washington and his B.S. in Microbiology from Colorado State University.